Navigation Links
Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
Date:5/5/2008

Retrospective Chart Review in 10 Geographic Regions throughout the United States Presented at Pediatric Academic Societies (PAS) Annual Meeting

HONOLULU, May 5 /PRNewswire/ -- MedImmune announced today that the company presented results from a retrospective chart review that evaluated the use of Synagis(R) (palivizumab) as a preventive measure against respiratory syncytial virus (RSV) disease in high-risk infants. RSV is a leading cause of viral respiratory infection among preterm infants.

Approximately 4,000 medical records from premature infants born at 32-to-35 weeks gestational age were reviewed. Fifty percent of those infants received Synagis. RSV prophylaxis was requested, but not administered in about one quarter of these infants. This group was found to have an RSV hospitalization rate of 8.3 percent, which was almost three times the rate of RSV hospitalization among those infants whose physicians did not request RSV prophylaxis (2.9 percent).

"These data support our position that pediatricians should have the final say in the diagnosis and care of their high-risk patients," said Jessie Groothuis, M.D., lead author of the study and MedImmune vice president, medical and scientific affairs, infectious disease. "Our findings indicate that after nearly 10 years of use of Synagis, the clinical judgment and experience of physicians serve to identify infants at high risk of RSV hospitalization, and should be relied upon to ensure patients get proper care."

This retrospective chart review, conducted in 10 geographic regions across the United States, included 376 physicians from 2005 to 2006. Data were presented at a poster session at the Pediatric Academic Societies (PAS) Annual Meeting being held this week in Honolulu, HI.

About Synagis

Synagis (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) can also occur.

Please see complete prescribing information at http://www.synagis.com.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
2. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
3. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
6. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
9. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
10. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... , ... Rob Lowe is a popular actor that has been in many ... educational purpose as the host of the “Informed” series. The program focuses on many ... the series focuses on thyroid cancer. , Although thyroid cancer is an uncommon type ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... Economics Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis ... (IRR) field. Offering practical takeaways to apply immediately to IRR programs, the report ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins of ... Year for her extraordinary compassion and lifelong dedication to serve others. Since 1997, ... for the prestigious award each year – identifying a CAREGiver who has exemplified ...
(Date:4/27/2017)... , ... April 27, 2017 , ... Are you investing ... spike in water-related accidents and drownings during the summer. While most of us assume ... these situations occur every day. Very few people are taking the time to learn ...
(Date:4/26/2017)... ... ... Journal of Oral Implantology – Tooth loss is not simply an ... complications with speech, eating, and overcompensation of mouth due to the deficiency. To combat ... number of tooth replacements increase, it is imperative to design an implant that will ...
Breaking Medicine News(10 mins):